Journal of Oncology

Clinical Study

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer

Table 1

Demographics and clinical characteristics of all randomised patients.
Docetaxel + capecitabinePaclitaxel + capecitabine
Median age (years)52 (35–65)53 (41–73)
Median weight (kg)6564.5
Median height (cm)165168.5
Median BSA (m2)1.711.71
Performance status (ECOG)
 0812
 I115
 II01
Estrogen receptor positive 1 2 / 1 9 1 2 / 1 8
Progesterone receptor positive 1 0 / 1 9 6 / 1 8
Prior postoperative radiotherapy 9 / 1 9 1 4 / 1 8
Prior radiotherapy for metastatic disease 7 / 1 9 2 / 1 8
Prior adjuvant chemotherapy 1 2 / 1 9 7 / 1 8
Prior chemotherapy for metastatic disease 1 2 / 1 9 1 1 / 1 8
Prior endocrine therapy for metastatic disease 1 4 / 1 9 1 2 / 1 8
Metastatic site
 Liver 7 / 1 9 9 / 1 8
 Lung 5 / 1 9 7 / 1 8
 Bone 6 / 1 9 1 0 / 1 8
 >2 metastatic sites 4 / 1 9 1 / 1 8
Diabetes 2 / 1 9 0 / 1 8
Thromboembolism 0 / 1 9 1 / 1 8
Cardiovascular disease 0 / 1 9 1 / 1 8
Time from diagnosis to first recurrence (months) (CI)55 (20–89)33 (16–50)